New hope for deadly brain tumors: Drug-Radiation combo trial opens
NCT ID NCT07589257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is to see how well the tumor is controlled and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells target deadly brain tumors in children
- Promising drug combo targets aggressive brain cancers in youth
- New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
- New vaccine hope for kids with deadly brain tumors
- Sound waves could open Brain's barrier to fight deadly tumor
- Engineered immune cells take on deadly brain tumors